- Home
- GROW vs MIRA Comparison
GROW vs MIRA Comparison
Compare GROW & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | MIRA |
|---|---|---|
| Founded | 1968 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 32.1M |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GROW | MIRA |
|---|---|---|
| Price | $2.98 | $0.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.8K | ★ 1.5M |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 900.00 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $14,399,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.42 | ★ N/A |
| Revenue Growth | ★ 32.77 | N/A |
| 52 Week Low | $2.23 | $0.60 |
| 52 Week High | $3.65 | $2.45 |
Technical Indicators
Market Signals| Indicator | GROW | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 52.12 |
| Support Level | $2.86 | $0.72 |
| Resistance Level | $3.05 | $0.82 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 30.65 | 20.47 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.